CASCARA: Castration Sensitive Carboplatin, Cabazitaxel and Abiraterone
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Emmanuel Antonarakis, MD
Masonic Cancer Center, University of Minnesota
Principal InvestigatorKOL profile →
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
8 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Mayo Clinic Arizona
Phoenix, Arizona, United States
- Northwestern University
Chicago, Illinois, United States
- University of Chicago
Chicago, Illinois, United States
- Tulane University
New Orleans, Louisiana, United States
- Masonic Cancer Center at University of Minnesota
Minneapolis, Minnesota, United States
- Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada, United States
- Thomas Jeferson University
Philadelphia, Pennsylvania, United States
- Lifespan Cancer Institute
Providence, Rhode Island, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 10 Oct 2019
- Primary completion
- 19 Jun 2023
- Completion
- 3 Apr 2025
- Last update posted
- 26 May 2026
- Registered enrollment
- 61
- Registry id
- NCT03934840
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.